Mirabegrón Stada (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms—including urinary urgency, frequency and urge urinary incontinence—in adult patients. The medication works by relaxing the detrusor muscle, thereby increasing bladder capacity and reducing involuntary contractions.

GNH USA supplies Mirabegrón Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering batch‑specific certificates of analysis and supporting import‑export compliance.

Mirabegron is indicated for conditions within the overactive bladder disease spectrum, where it improves bladder storage function.

Overactive bladder: reduces urgency episodes and increases bladder capacity. Urinary urgency: lessens the frequency of sudden urges to void. Urge urinary incontinence: decreases the number of incontinence episodes.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Urinary tract infection: increased incidence reported. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation. - Constipation: decreased bowel motility.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate episodes. - Severe hypertension: markedly high blood pressure requiring medical attention. - Angioedema: swelling of face, lips, or throat. - Allergic reactions: rash, pruritus, or anaphylaxis. - Myocardial infarction: rare cardiac event.

Before initiating therapy, consider the following precautions: - Cardiovascular assessment: monitor blood pressure regularly. - Renal function evaluation: adjust use in severe renal impairment. - Urinary retention risk: avoid in patients with significant bladder outlet obstruction. - Concomitant antihypertensives: be aware of possible additive blood‑pressure effects. - Drug‑interaction review: assess for CYP2D6 inhibitors or inducers. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Mirabegron may interact with several drug classes; review patient medication lists carefully.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Combined anticholinergics: heightened risk of urinary retention. - Antihypertensive agents: possible reduction in blood‑pressure control.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower mirabegron levels. - NSAIDs: may exacerbate hypertension. - Diuretics: potential additive effect on blood‑pressure regulation.